Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease

Nature Reviews Urology

Volumn 7, Issue 6, 2010, Pages 300-

  Payton, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; DOCETAXEL; MDV 3100; PLACEBO; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 77953584353     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.69     Document Type: Article

References (1)

1. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446 (2010)